

## Grant Confirmation

1. This **Grant Confirmation** is made and entered into by **the Global Fund to Fight AIDS, Tuberculosis and Malaria** (the "Global Fund") and **Department of Economic Affairs, Ministry of Finance of India** (the "Principal Recipient") on behalf of India (the "Grantee"), pursuant to the Framework Agreement, dated as of 1 October 2015, as amended and supplemented from time to time (the "Framework Agreement"), between the Global Fund and the Grantee, to implement the Program set forth herein. The Grant Confirmation is effective as of the earlier of the start date of the Implementation Period (as defined below) or the date of the Global Fund's signature below, and Program Activities shall not commence prior to the start date of the Implementation Period, unless otherwise agreed in writing by the Global Fund.
  
2. **Single Agreement.** This Grant Confirmation, together with the Integrated Grant Description attached hereto as Schedule I, sets forth the provisions (including, without limitation, policies, representations, covenants, Program Activities, Program budget, performance framework, and related implementation arrangements) applicable to the Program, and forms part of the Grant Agreement. Each capitalized term used but not defined in this Grant Confirmation shall have the meaning ascribed to such term in the Framework Agreement (including the Global Fund Grant Regulations (as amended from time to time), available at [https://www.theglobalfund.org/media/5682/core\\_grant\\_regulations\\_en.pdf](https://www.theglobalfund.org/media/5682/core_grant_regulations_en.pdf)). In the event of any inconsistency between this Grant Confirmation and the Framework Agreement (including the Global Fund Grant Regulations (as amended from time to time)), the provisions of this Grant Confirmation shall govern unless expressly provided for otherwise in the Framework Agreement.
  
3. **Grant Information.** The Global Fund and the Grantee hereby confirm the following:

3.1	Host Country or Region:	Republic of India
3.2	Disease Component:	HIV/AIDS
3.3	Program Title:	Strategic Augmentation of HIV And STI (SAHAS 2.0)
3.4	Grant Name:	IND-H-NACO
3.5	GA Number:	3884
3.6	Grant Funds:	Up to the amount of USD 100,290,494 or its equivalent in other currencies
3.7	Implementation Period:	From 1 April 2024 to 31 March 2027 (inclusive)
3.8	Principal Recipient:	Department of Economic Affairs, Ministry of Finance of India

		33 A1, North Block 110011 New Delhi Republic of India Attention: Nidhi Kesarwani Director (NACO) Email: <a href="mailto:dir@naco.gov.in">dir@naco.gov.in</a>
3.9	Fiscal Year:	1 April to 31 March
3.10	Local Fund Agent:	Price Waterhouse LLP Building 8, 8th Floor, Tower-B DLF Cyber City 122002 Gurgaon Republic of India Attention: Heman Sabharwal Team Leader Telephone: +911244620148 Facsimile: +91-124-462-0620 Email: <a href="mailto:heman.sabharwal@pwc.com">heman.sabharwal@pwc.com</a>
3.11	Global Fund contact:	The Global Fund to Fight AIDS, Tuberculosis and Malaria Global Health Campus, Chemin du Pommier 40 1218 Grand-Saconnex, Geneva, Switzerland Attention: Urban Weber Department Head Grant Management Division Telephone: +41-587911700 Facsimile: +41-445806820 Email: <a href="mailto:urban.weber@theglobalfund.org">urban.weber@theglobalfund.org</a>

4. **Policies.** The Grantee, acting through the Principal Recipient, shall implement the Program in accordance with the National Strategic Plan for HIV/AIDS and STI (the "National Strategic Plan") set forth in Schedule II and shall take all appropriate and necessary actions to comply throughout the Implementation Period with: (1) the Global Fund Guidelines for Grant Budgeting (2023, as amended from time to time) and the "Budgeting and Financial Reporting Special Provisions" set forth in Schedule III); (2) the Health Products Guide (2018, as amended from time to time) in respect of Grant Funds directly disbursed by the Global Fund for the procurement of Health Products; and (3) any other policies, procedures, regulations and guidelines, which the Global Fund may communicate in writing to the Grantee and the Principal Recipient, from time to time.
5. **Representations.** In addition to the representations set forth in the Framework Agreement (including the Global Fund Grant Regulations (as amended from time to time)), the Grantee and the Principal Recipient hereby represents that the Principal Recipient has all the necessary power, has been duly authorized by or obtained all necessary consents, approvals and authorizations to execute and deliver this Grant Agreement and to perform all the obligations on behalf of the Grantee under this

Grant Confirmation. The execution, delivery, and performance by the Principal Recipient on behalf of the Grantee of this Grant Confirmation do not violate or conflict with any applicable law, any provision of the Grantee's and Principal Recipient's constitutional documents, any order or judgment of any court or any competent authority, or any contractual restriction binding on or affecting the Grantee or the Principal Recipient.

6. **Covenants**. The Global Fund and the Grantee further agree that:

6.1 Personal Data

(1) Principles. The Principal Recipient, acknowledges that Program Activities are expected to respect the following principles and rights ("Data Protection Principles"):

(a) Information that could be used to identify a natural person ("Personal Data") will be: (i) processed lawfully, fairly and transparently; (ii) collected for specified, explicit and legitimate purposes and not further processed in a manner not compatible with those purposes; (iii) adequate, relevant and limited to what is necessary for the purposes for which they are processed; (iv) accurate and, where necessary, kept up to date; (v) kept in a form which permits identification of the individuals for no longer than is necessary for the purposes for which the Personal Data is processed; and (vi) processed in a manner that ensures appropriate security of the Personal Data; and

(b) Natural persons are afforded, where relevant, the right to information about Personal Data that is processed; the right to access and rectify or erase Personal Data; the right to data portability; the right to confidentiality of electronic communications; and the right to object to processing.

(2) Limitations. Where collection and processing of Personal Data is required in order to implement Program Activities, whether by the Principal Recipient, a Sub-recipient, or Supplier, the Principal Recipient should respect the Data Protection Principles:

(a) to the extent that doing so does not violate or conflict with applicable law and/or policy; and

(b) subject to the Principal Recipient balancing the Data Protection Principles with other fundamental rights in accordance with the principle of proportionality, taking into account the risks to the rights and freedoms of natural persons.

6.2 With respect to Section 7.6 (Right of Access) of the Global Fund Grant Regulations (as amended from time to time), prior to the collection of Personal Data and at all times thereafter, the Principal Recipient shall take all necessary actions to ensure that the transfer of such information to the Global Fund does not violate any applicable law or regulation.

6.3 The Program budget may be funded in part by Grant Funds disbursed under a previous Grant Agreement, which the Global Fund has approved to be used for the Program under the current Grant Agreement ("Previously Disbursed Grant Funds"), as well as additional Grant Funds up to the amount set forth in Section 3.6. hereof. Accordingly, the Global Fund may reduce the amount of Grant Funds set forth in Section 3.6. hereof by the amount of any Previously Disbursed Grant Funds.

Previously Disbursed Grant Funds shall be governed by the terms of this Grant Agreement.

6.4 Use of Grant Funds. Grant Funds shall be accounted for and used solely for the implementation of the National Strategic Plan (NACP V) in accordance with the provisions of the Global Fund Grant Regulations (2014) and the Global Fund Guidelines for Grant Budgeting (2023, as amended from time to time), to the extent not conflicting with those set forth in this Grant Confirmation.

6.5 Disbursements. Section 3.3(1) of the Global Fund Grant Regulations (2014) shall not apply with respect to this Program and the following provisions shall apply instead:

(1) The first annual funding decision (“AFD”) is determined in 2024, covering the budgeted amounts for expected results under the disbursement linked indicators (“DLI”) set forth in Schedule V of this Grant Agreement, for the first year of the Implementation Period. Each following AFD will be determined to cover the budgeted amounts for expected results under the DLIs set forth in Schedule V of this Grant Agreement for the second and third year, respectively. An adjustment to each AFD may be made by the Global Fund based on the verification and validation of the results of the previous year of the Implementation Period.

(2) Disbursement methodology. Disbursements shall be made pursuant to the disbursement methodology set forth in Schedule IV of this Grant Confirmation (the “Disbursement Methodology”).

(3) Disbursement Requests. Notwithstanding the National Strategic Plan (NACP V) budget and the Disbursement Methodology or anything in this Grant Confirmation to the contrary, the timing and amount of any Disbursements shall be determined by the Global Fund at its sole discretion. The Global Fund will not make any Disbursement unless:

(a) the Principal Recipient has submitted to the Global Fund, in form and substance satisfactory to the Global Fund, a request for Disbursement, signed by a duly authorized signatory, at a time acceptable to the Global Fund;  
(b) the Global Fund has determined at its sole discretion that funds sufficient to make the Disbursement are available to the Global Fund from its donors for such purpose at the time of the Disbursement;

(c) the Grantee and the Principal Recipient have fulfilled, in form and substance satisfactory to the Global Fund, all requirements for such Disbursement within relevant deadlines;

(d) the Principal Recipient has provided to the Global Fund all the relevant reports that were required prior to the date of the request for Disbursement; and  
(e) the Principal Recipient has demonstrated that it has achieved programmatic results consistent with the targets for indicators set forth in Schedule I.

(4) Verification of results. Any Disbursement shall be subject to the achievement of the results that are reported by the Principal Recipient and verified by the Global Fund (or any third-party verification agency as approved in writing by the Global Fund) using the methodology described in Schedule V, which may be refined or

amended from time to time by the Global Fund in consultation with the Grantee and partners. The Principal Recipient shall support, collaborate, and cooperate with third parties and the process through which results are verified.

(5) Catastrophic results. In the event that the results reported by the Principal Recipient are deemed, at the sole discretion of the Global Fund, to be catastrophic, the Global Fund may elect to apply the remedies established in Article 10 of the Global Fund Grant Regulations (2014), or may decide to disburse only a percentage of the achieved results to cover essential service delivery and targeted recovery costs, based on a prompt review of the reasons of the poor results, changes that will be made to the Program, total available Grant Funds for the Program and stocks of Health Products in the Host Country.

(6) Fraud, theft, or misuse. If fraud, theft, or misuse of public funds is identified and verified in the Grantee's National AIDS Diseases Control Program, the Grantee shall be required to repay to the Global Fund an amount equal to the portion of the amount of funds lost to fraud, theft or misuse that is proportional to the Global Fund's contribution to the implementation of the National AIDS Diseases Control Program, as applicable.

6.6 Co-mingling. With reference to Section 3.4(1)(d) of the Global Fund Grant Regulations (2014), the Global Fund hereby agrees to the co-mingling of Grant Funds disbursed for the purposes of the Program with other funds.

6.7 Use of interest. Notwithstanding Section 3.4(2) of the Global Fund Grant Regulations (2014), any interest accrued on Grant Funds may be used for Program purposes without the prior written approval of the Global Fund.

6.8 Use of revenue. Notwithstanding Section 3.4(3) of the Global Fund Grant Regulations (2014), any revenues earned by the Principal Recipient or Sub-recipients from any Program Activities may be used for Program purposes without the prior written approval of the Global Fund.

6.9 Gains or losses deriving from Treasury management. The Grantee bears full responsibility for the management of the risk of losses related to treasury management, including but not restricted to foreign exchange risk.

6.10 Periodic and ad hoc reports. Section 6.2(1) of the Global Fund Grant Regulations (2014) shall not apply with respect to this Grant Agreement and the following provisions shall apply instead:

(1) The Principal Recipient shall provide to the Global Fund the reports specified in Sections 6.10(2) – 6.10(4) below. In addition, the Principal Recipient shall provide to the Global Fund such other information and reports at such times as the Global Fund may request. From time to time, the Global Fund may provide to the Principal Recipient guidance on the acceptable frequency, form and content of the reports required under this Section. The Principal Recipient shall provide to the CCM a copy of all reports that the Principal Recipient submits to the Global Fund under the Grant Agreement.

(2) No later than 31 May 2025, 2026, and 2027, respectively, the Principal Recipient shall provide to the Global Fund, in form and substance satisfactory to the Global Fund, a report, in which the Principal Recipient shall:

(a) show the progress towards the achievement of key performance indicators as set forth in the Performance Framework included in Schedule I for the preceding year of the Implementation Period, providing relevant information on the reported data and the measurement methods, such as the robustness and reliability of data quality mechanisms, using the Global Fund's Progress Update template;

(b) include an Annual Financial Report ("AFR") for the previous year of the Implementation Period which shall compare the relevant portion of the Summary Budget against the Global Fund confirmed amounts under the DLIs achieved and verified as expenditures for the period specified by the Global Fund; and

(c) show the progress towards the fulfilment of any requirements set forth in this Grant Confirmation and any relevant management actions.

(3) For each Fiscal Year during the Implementation Period, the Principal Recipient shall submit to the Global Fund, in form and substance satisfactory to the Global Fund, a report setting out the Grantee's approved annual budget towards implementation of the National Strategic Plan, within 45 calendar days of the Grantee's approval of the budget.

(4) Any exception request to Section 6.10 of this Grant Confirmation has to be submitted in writing by the Grantee, and approval of such deviations shall be at the sole discretion of the Global Fund.

6.11 Audits. Sections 7.2, 7.3 and 7.4 of the Global Fund Grant Regulations (as amended from time to time) shall not apply with respect to this Grant Agreement and the following provisions shall instead apply:

(1) The Program Boundaries are defined as follows: (a) antiretroviral medicines as recommended in antiretroviral therapy guidelines issued by the National AIDS Control Organization ("NACO"), on behalf of the Grantee, or otherwise recommended for use in the antiretroviral therapy program by NACO; (b) viral load equipment, test and consumables as outlined in the "National Guidelines for HIV-1 Viral Load Laboratory Testing" and required for conducting viral load tests for routine monitoring of patients on antiretroviral therapy; (c) diagnostic products for detection and diagnosis of HIV infection (including dual HIV/Syphilis RDTs) and condoms in line with the national guidelines; and (d) activities implemented by the Sub-recipients on behalf of the Principal Recipient, of key Program interventions, including supply and chain management, strengthening Lab for NACP, procurement of vehicles, evaluations, systems strengthening and capacity building, strategic communication to enhance prevention and management of Sampoorna Surakhsha Kendra centers. Annual financial audits of activities (a) to (c) of the Program Boundaries shall be conducted by the Comptroller and Auditor General of India (the "Auditor"), on the basis that:

(a) the periods under audit shall cover each year of the Implementation Period starting on 1 April and ending on 31 March and shall be completed within 9 months after the Fiscal Year end date; and

(b) the financial audit shall cover the expenditures of activities (a) through (c) of the Program Boundaries, independent of the source of funds being provided by the Principal Recipient, governmental stakeholders, or the Global Fund.

(2) No later than 30 September 2024, the Grantee shall ensure that the Auditor shall agree with the Global Fund, the terms of reference for the annual audits to be conducted under Section 6.11(1); and no later than 30 June 2025, 2026, and 2027 the Grantee shall communicate and agree with the Global Fund the scope of expenditures to be audited. In the even the Program Boundaries scope is changed, this should be reflected in the corresponding audit period.

(3) No later than 30 September 2025, 2026, and 2027, respectively, the Principal Recipient shall furnish to the Global Fund, the annual audit report for the Program interventions implemented by each Sub-recipient for the previous fiscal year.

(4) The cumulative expenditures incurred under the Program Boundaries Section 6.11(1), as confirmed through the annual financial audits conducted by the Auditor and the audits of the Sub-recipients pursuant to Section 6.11(3) above, shall not be less than the total cumulative amount disbursed and/or payable under the Grant under the DLIs. In the event that the Grantee's expenditure is less than the amount corresponding to the achieved results under the DLIs, the Global Fund may in its sole discretion reduce any subsequent disbursements by the equivalent shortfall amount (the "Shortfall Amount") or request reimbursement by the Grantee of the Shortfall Amount to the Global Fund and the Grantee shall reimburse the Shortfall Amount to the Global Fund within 60 calendar days of the Global Fund's request.

(5) No later than 30 September 2025, 2026, and 2027, respectively, the Principal Recipient shall furnish to the Global Fund, the Central Medical Services Society ("CMSS") entity audit report for the previous Fiscal Year.

(6) No later than 30 September 2025, 2026, and 2027, respectively, the Principal Recipient shall furnish to the Global Fund statutory audit reports and management letters of the Grantee's State AIDS Control Societies ("SACS") for Maharashtra, Karnataka, Tamil Nadu, Delhi, and Uttar Pradesh for the previous Fiscal Year.

(7) In addition to Section 7.6 of the Global Fund Grant Regulations (as amended from time to time), the Principal Recipient shall ensure that the Office of the Inspector General of the Global Fund will have explicit permission to access the working papers of the Auditor for assurance validation, including the annual audit plan and other relevant internal audit reports.

6.12 Miscellaneous provisions.

(1) The Grantee acknowledges and agrees that for the duration of the Implementation Period:

(a) All antiretrovirals procured by the Grantee will be subject to mandatory pre or post shipment quality control testing;

(b) The quality of Health Products will be monitored after distribution of such Health Products. Samples of antiretrovirals will be drawn at various levels of the supply chain and tested at an independent laboratory; and

(c) The Grantee shall work with the SACS to increase the rate of facilities reporting through the Inventory Management System (“IMS”). It is expected that by 31 March 2027, at least 90% of all facilities will use and report inventory related data through the IMS.

6.13 The Principal Recipient, on behalf of the Grantee, remains solely responsible and accountable to the Global Fund for the implementation of the Grant and for compliance with all obligations contained in this Grant Agreement.

*[Signature Page Follows.]*



IN WITNESS WHEREOF, the Global Fund and the Principal Recipient, acting on behalf of the Grantee, have caused this Grant Confirmation to be executed and delivered by their respective duly authorized representatives on their respective date of signature below.

The Global Fund to Fight AIDS,  
Tuberculosis and Malaria

Department of Economic Affairs,  
Ministry of Finance of India  
on behalf of India

By: M.A. Eldon-Edgington

Name: Mark Eldon-Edgington

Title: Head, Grant Management  
Division

Date: Mar 29, 2024

By: Raj Mahmapat Ray

Name: Raj Mahmapat Ray

Title: Deputy Secretary

Date: 21/3/24

Acknowledged by

By: \_\_\_\_\_

Name: Apurva Chandra

Title: Chair, Country Coordinating Mechanism of Republic of India

Date:

By: Anandi Yuvaraj

Name: Anandi Yuvaraj

Title: Civil Society Representative, Country Coordinating Mechanism of Republic of  
India

Date: 27/03/24

**Schedule I**  
**Integrated Grant Description**

**A. PROGRAM DESCRIPTION**

**1. Background and Rationale for the Program**

India's National AIDS and STD Control Program (NACP), currently in fifth phase of implementation, is a comprehensive three-pronged programme in the domains of prevention-detection-treatment with strategic information driven focus on the locations and populations for tailored interventions. The NACP Phase-V will take the national AIDS and STD response till Financial Year 2025-26 towards the attainment of United Nations' Sustainable Development Goals 3.3 of ending the HIV/AIDS epidemic as a public health threat by 2030. Attainment of 95-95-95 by 2025 is a key outcome target envisioned under NACP-V.

Under NACP Phase-V, while the existing interventions are being sustained, optimized, and augmented; newer strategies are being adopted, piloted, and scaled-up under the programme to respond to the geographic and community specific needs and priorities. The HIV and AIDS (Prevention and Control) Act, 2017 continues to be the cornerstone of the national response to HIV and STI epidemic in NACP Phase-V which provides the enabling framework to break down barriers driving delivery of a comprehensive package of services in an ecosystem free of stigma and discrimination.

Guiding Principles of NACP Phase-V (2021-26): Eight guiding principles are central to strategies and activities to attain the specific targets -

1. Keep beneficiary and community in center
2. Break the silos, build synergies
3. Augment strategic information-driven planning, implementation, monitoring, and mid- course corrections
4. Prioritize and optimize through high-impact programme management and review
5. Leverage technology and innovation as critical enablers
6. Enhance and harness partnership
7. Integrate gender-sensitive response
8. Continue fostering technical arrangements and institutions

**2. Goals, Strategies and Activities**

The NACP Phase-V aims to reduce annual new HIV infections and AIDS-related mortalities by 80% by 2025-26 from the baseline value of 2010. The NACP Phase-V also aims to attain dual elimination of vertical transmission, elimination of HIV/AIDS related stigma while promoting universal access to quality STI/RTI services to at-risk and vulnerable populations.

The specific objectives of the NACP Phase-V are as below:

a. HIV/AIDS prevention and control

- i. 95% of people who are most at risk of acquiring HIV infection use comprehensive prevention
- ii. 95% of HIV positive know their status, 95% of those who know their status are on treatment and 95% of those who are on treatment have suppressed viral load
- iii. 95% of pregnant and breastfeeding women living with HIV have suppressed viral load towards attainment of elimination of vertical transmission of HIV
- iv. Less than 10% of people living with HIV and key populations experience stigma and discrimination

b. STI/RTI prevention and control

- i. Universal access to quality STI/RTI services to at-risk and vulnerable populations
- ii. Attainment of elimination of vertical transmission of syphilis

Reference may be made to Pg. 38 of NACP V Strategy Document for a snapshot on goals, objectives, and strategic interventions.

**3. Target Group/Beneficiaries**

People infected and affected with HIV

Key population (High-risk and bridge population)

'At-risk' population

General population

Pregnant women

**B. PERFORMANCE FRAMEWORK**

Please see attached.

**C. SUMMARY BUDGET**

Please see attached.

## Schedule II

### National Strategic Plan for HIV/AIDS and STI



NACP\_V\_Strategy\_Bo  
oklet.pdf

**Schedule III**  
**Budgeting and Financial Reporting Special Provisions**

1. The Grant Funds are provided to support the National Strategic Plan (NACP V), and the use of Grant Funds is flexible within the parameters of the Grant Agreement.
2. During implementation, budgetary changes to the National Strategic Plan (NACP V) budget are allowed without prior approval from the Global Fund.
3. As disbursements are solely based on performance, no cash balance reporting will be required.

**Schedule IV**  
**Disbursement Methodology**

1. The Grant Funds will be disbursed annually or at such other time as the Global Fund shall deem appropriate at its sole discretion.

2. The application of the disbursement methodology might result in a reduction of the total amount of Grant Funds set forth in Section 3.6 of the Grant Confirmation, and in consequence in a reduction of the Grant Funds to be disbursed for any subsequent period until the end of the Implementation Period, after the reporting and verification of the programmatic results.

3. The first AFD will be determined in 2024, covering the budgeted amounts for expected results under the DLIs as set forth in Schedule V of this Grant Agreement for the first year of the Implementation Period. Each following AFD will be determined to cover the budgeted amounts for expected results under the DLIs set forth in Schedule V of this Grant Agreement for the second and third year, respectively. An adjustment to each AFD may be made by the Global Fund based on the verification and validation of the results of the previous year of the Implementation Period.

4. Based on verified results, the disbursement amount will be calculated for each indicator based on the Results Framework set forth in Schedule V of this Grant Confirmation.

5. Unless otherwise determined by the Global Fund in its sole discretion, the following formula may be used for calculating the amount to be disbursed, or some other scalable formula, according to the performance of each indicator:

- If:

- the indicator rating is equal to or greater than 90%, then the performance for that indicator will be considered as 100%, for the reporting period, unless paragraph 6 of this Schedule shall apply,

- If:

- The indicator rating is less than 90%, then performance of the indicator will be equal to the indicator rating for the reporting period,

Disbursement for the reporting period, in both cases, will be calculated as:

$$\text{Disbursement} = \sum_{i=1}^n (\text{budget DLI } i * \text{performance DLI } i)$$

6. In cases where the achievement rate of a given indicator is less than 100% in a particular year and greater than 100% in the subsequent year, the Disbursement amount will be determined on a cumulative basis which shall not exceed the cumulative budget allocated for the reporting year for that DLI.

7. The Global Fund has sole discretion to determine the achievement rate for an indicator, and therefore the commensurate disbursement amount (if any) where:

- a. Results are reported after three months of the expected date for the routine programmatic report. Any exception has to be submitted in writing by the CCM, and approval of such deviations shall be at the discretion of the Global Fund;
- b. Fraudulent reporting is suspected and/or identified. The Global Fund also reserves the right to conduct a data quality audit/additional data quality review at any stage, including after expiration of the Implementation Period; and
- c. The Global Fund has determined non-compliance to open access to data.

**Schedule V**

**Independent Data Quality and Quality of Care Review**

1. Disbursement Linked Indicators

a. The following Disbursement Linked Indicators shall apply as set out in the Results Framework below:

*Table 1: Indicators for Payment for Results*

<b>Results Framework</b>						
<b>DLI</b>	<b>DLI Baseline (2022/2023)</b>	<b>DLI Targets</b>			<b>Total 3 year- budget (in USD)</b>	<b>Comment</b>
		<b>Year 1 (2024- 2025)</b>	<b>Year 2 (2025- 2026)</b>	<b>Year 3 (2026- 2027)</b>		
DLI1: Number of people (adults and children) on ART at the end of the reporting period	1,680,083	1,760,000	1,840,000	1,920,000		Numerator: Number of PLHIV alive and on ART at the end of the reporting period (public and private sector PLHIV on ART).  The indicator will be reported on an annual basis.  Source of data: CST MPR (3.10) and private sector PLHIV on ART.



<b>Allocated total amount DLI 1</b>		US\$18,546,793	US\$18,629,560	US\$21,124,522	US\$58,300,875	
<b>DLI 2:</b> Percentage of people living with HIV and on ART who are virologically suppressed	93%	93%	94%	95%		<p>Numerator: Number of people living with HIV on ART for at least 6 months and with at least one routine VL test result who have virological suppression (&lt;1000 copies/mL) during the reporting period.</p> <p>Denominator: Number of people living with HIV on ART for at least 6 months with at least one routine VL result during the reporting period.</p> <p>The indicator will be reported on an annual basis.</p> <p>Source of data: VL lab data/SOCH</p> <p>NACO will report on Percentage of people living with HIV and on ART with viral load test result. To</p>

						<p>ensure adequate coverage, it is expected that for each year, 75% of the PLHIV on ART receive a viral load test in each reporting period.</p> <p>The baseline (2023) is 1,230,249 which is 73% of PLHIV on ART.</p> <p>The PR should provide an update on the viral load testing coverage to validate this indicator.</p>
<b>Allocated total amount DLI 2</b>		US\$12,585,645	US\$11,364,537	US\$11,931,154	US\$35,881,336	
<b>DLI 3:</b>  Number of at-risk-population registered at 'Sampoorna Suraksha' Centers during the	N/A	150,000	250,000	330,000		<p>The SSK serves the HIV negative population at risk.</p> <p>As per the national guideline: The population "At Risk" for HIV &amp; STIs is defined as 'any individual who is at risk of acquiring HIV or STI due to risky behaviors of self or partner(s)'. This includes the core population, the</p>

reporting period.					<p>bridge population, their spouses / partners, and other populations who are engaging in risky behaviors.</p> <p>SSK clients include the following among others:</p> <ul style="list-style-type: none"> <li>• Adolescent and Young Population</li> <li>• Unreached KP and their spouses/partners/children</li> <li>• Spouses/partners of PLHIV</li> <li>• General population at risk of HIV/STI, with special focus on single male/woman migrant</li> <li>• Clients referred from Designated STI/RTI clinics (DSRC)</li> <li>• Self-walk-in clients who have been identified at risk and are HIV negative</li> <li>• Clients referred from other departments ICTC</li> </ul>
-------------------	--	--	--	--	---

					<p>walk-in clients at high risk and tested negative</p> <ul style="list-style-type: none"> <li>• Pregnant Women at high risk and tested negative</li> <li>• STI clients</li> <li>• Persons with co-morbidity (TB, Hep B/C).</li> </ul> <p>Those not included are:</p> <ul style="list-style-type: none"> <li>• Clients associated with targeted Interventions (TI) and Linked Workers Scheme (LWS)</li> <li>• Clients HIV positive</li> <li>• Clients not at high risk</li> </ul> <p>Services include:</p> <ul style="list-style-type: none"> <li>• Routine STI Assessment &amp; Services</li> <li>• STI testing (HIV and syphilis)</li> <li>• Risk assessment</li> <li>• Counselling</li> </ul>
--	--	--	--	--	--

						<ul style="list-style-type: none"> <li>• Routine follow up</li> <li>• Virtual services</li> </ul> <p>Numerator: Number of at-risk HIV negative population registered at SSK during the reporting period.</p> <p>The indicator will be reported on an annual basis.</p> <p>This information will be derived using the number of at-risk negative population registered in all Sampoorna Suraksha Kendras (SSK) based on monthly reporting.</p> <p>Source of data: NORMS/SSK data tool</p>
<b>Allocated total amount DLI 3</b>		US\$1,702,959	US\$2,009,956	US\$2,395,368	US\$6,108,283	
<b>DLI Total Amounts</b>	<b>Allocated</b>	US\$32,835,397	US\$32,004,053	US\$35,451,044	US\$100,290,494	

In addition to reporting the DLIs stated above, the Principal Recipient shall report to the Global Fund on the HIV indicators of the Performance Framework attached to this Grant Confirmation. Performance against these non-DLI indicators present in the PF will not affect disbursement.

## 2. Programmatic reporting of results

a. The Principal Recipient shall report results within 60 calendar days of the end of the reporting period (by 30 May 2025, 2026, and 2027, respectively, for results of the 12-month prior period from 1 April to 31 March (inclusive)), except when the Performance Framework set forth in Schedule I states otherwise.

b. The Principal Recipient will be requested to provide a qualitative annual progress report with analysis of the robustness and reliability of data quality mechanisms, program challenges and successes by 30 May 2025, 2026, and 2027, respectively, of the 12-month prior period from 1 April to 31 March (inclusive).

c. The Principal Recipient shall conduct a mid-term program review in-country during the period from 1 April 2025 to 30 June 2025, with the Grantee and partners to discuss program progress and propose adjustments to the National Strategic Plan (NACP V) or annual work plans as needed.

d. During the annual review of results, based on new epidemiological data, World Health Organization (“WHO”) updated estimations, new WHO guidelines and/or other predefined National Strategic Plan (NACP V) costing scenarios, the Principal Recipient and the Global Fund may, on an exceptional basis, agree to revise targets upwards or downwards.

## 3. Verification of results and data quality

a. This section sets out the Global Fund’s key principles that will inform verification of the Results Framework.

b. The Protocol for HIV verification used under the GC 6 grant will be reviewed and updated as necessary by the Global Fund in consultation with the Grantee (the “Protocol”).

c. The results verification will be carried out by the Local Fund Agent.

### *Sample Design*

d. A multi-stage purposive cluster sample design will be clarified in the protocol. Multi-stage will be applied where states will be sampled first and then at a second stage, health facilities will be sampled.

e. The concept of purposive sample design will be applied because only states and health facilities sites which meet the inclusion criteria will be eligible for assessment. The inclusion criteria are likely to be: (i) Epidemiological high burden states will be included in the sampling frame; and (ii) secondly, within the selected states facilities with high case load will be integrated in the facility sampling framework.

f. The national definition for high burden states and high volume/case load sites will be applied.

g. High burden states will be selected based on the data tabulation from ART centers nationally.

h. Within the selected states, a probability proportionate to size sampling will be applied on the sampling framework built around the high case load sites.

#### *Quantitative Data Verification Tool*

i. A quantitative tool for verification has been developed based on adaptation of the WHO Data Quality Review Toolkit and/or other tools applied by HIV partners.

j. The verification tool contains standardized quantitative data assessment and summary results of the data verification of the indicator(s) as expressed as a verification factor at the health facility level (verification factor = recounted results / reported results).

#### *Data Quality Assessment*

k. Data quality will be assessed by verifying results per indicator at facility centers. The results will be adjusted depending on the data quality ratings.

l. The adjustment range and approach will be negotiated and agreed with the country during grant making. However, the following illustrates how this will be applied: overall good data quality (verification factor of <10%) no adjustment is made to the reported result for the indicator assessed.

m. The national verification factor for an indicator will be obtained through calculating the weighted mean of individual health facility verification factors or other appropriate methods for deriving the weighted estimates of the accuracy for the assessed indicator.

n. The verification factor will be used to derive the resulting overall absolute weighted error per indicator which will be taken into account to adjust the reported results.

#### *LFA verification under the Program Boundaries*

o. LFA verification shall include: (i) The verification of advances/payments executed by NACO to the CMSS for procurements falling under the Program Boundaries. The same would be carried out at NACO by checking the supporting documents and entry in the Government's central accounting (PFMS) system and (ii) Verification at CMSS related to the process of placing the purchase orders (procurement process) as well as delivery of goods and payments to suppliers from the documents available at CMSS.